An Open-label, Mass Balance Study to Investigate the Absorption, Metabolism and Excretion of [14C] MT-1303 After a Single Oral Dose to Healthy Male Subjects.
Phase of Trial: Phase I
Latest Information Update: 20 Mar 2015
At a glance
- Drugs Amiselimod (Primary)
- Indications Multiple sclerosis
- Focus Pharmacokinetics
- Sponsors Mitsubishi Tanabe Pharma Corporation
- 16 Mar 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 21 Nov 2014 New trial record